Immunotherapy – using small molecules and biologics that provide therapeutic benefit by focusing the capabilities of the immune system on the tumor – promises to transform cancer care, having already shown striking patient responses. This paper provides an overview of the clinical immunotherapy landscape and offers goals and cautions to inform the development of therapies that enlist the power of the immune system to attack lethal and resistant forms of cancer.


  • Brad Smith, Ph.D., Vice President of Translational Medicine, Quintiles 
  • Chris A. Learn, Ph.D., PMP, Senior Clinical Project Manager, Quintiles 
  • Eric Groves, MD, Ph.D., Vice President, Center for Integrated Drug Development, Quintiles